Oct 2026· Signal Transduction and Targeted Therapy· Vol 11· 0 citations· 38 references
Medicine
TL;DR
It is shown that spatial CD8+ T-cell exclusion is associated with lower objective response rates and shorter progression-free survival in ICB-treated NSCLC patients, and further evaluation of spatial immune contexture as a complementary biomarker in ICB-treated patients is supported.
Abstract
Immune checkpoint blockade (ICB) has reshaped the treatment of advanced non-small cell lung cancer (NSCLC), yet durable benefit remains limited to a subset of patients. One major pattern of resistance is immune exclusion, in which CD8+ T cells accumulate in stromal regions but fail to penetrate tumor nests. Here, using discovery and non-overlapping internal validation cohorts of ICB-treated NSCLC patients, we show that spatial CD8+ T-cell exclusion is associated with lower objective response rates and shorter progression-free survival. To characterize the molecular programs linked to this phenotype, we integrated GeoMx spatial transcriptomics, bulk transcriptomic profiling, TCR-probe expression analysis, multiplex immunohistofluorescence, and single-cell spatial neighborhood analyses. Compared with infiltrated tumors, immune-excluded tumors showed reduced expression of genes encoding antigen-presentation machinery in the tumor compartment, including HLA class I genes and TAP1, with an altered relationship between IFN-γ-associated transcriptional signals and expression of antigen-presentation machinery. At the stromal level, excluded tumors were enriched for myofibroblastic cancer-associated fibroblast programs and peri-epithelial collagen-rich architecture, whereas infiltrated tumors displayed immune-supportive stromal signatures. CD8-enriched regions from excluded tumors showed reduced metabolic activation and lower TCR-probe expression diversity, without a marked increase in canonical exhaustion markers. These findings provide an integrated, compartment-resolved description of tumor-intrinsic and stromal features associated with immune exclusion in NSCLC and support further evaluation of spatial immune contexture as a complementary biomarker in ICB-treated patients.
This study uncovered previously unrecognized immunosuppressive cell populations and key immune regulators that advance understanding of CRC immune evasion and highlight potential targets for personalized immunotherapy.
Dominika Miroszewska, Shi-Yang Song, Víctor Urbiola-Salvador et al.· British Journal of Cancer· 0 citations
Large B-cell lymphomas (LBCLs) comprise biologically heterogeneous malignancies whose clinical behavior reflects interactions between malignant B cells and their surrounding immune and stromal compartments. Single-cell sequencing, spatial transcriptomics, and multiplex imaging have revealed distinct microenvironmental...
K. Pansy, Matthias Zänker, Antonella Zupo et al.· Cancer Biome and Targeted Th...· 0 citations
Immune checkpoint inhibitor (ICI) therapy has transformed melanoma treatment, yet many patients either fail to respond or develop resistance after an initial response. The cellular and spatial determinants within the tumor microenvironment (TME) that underlie these divergent ICI therapy outcomes remain poorly defined....
Sajib Chakraborty, E. Corrales, I. Godbole et al.· Genome Medicine· 0 citations
FAP+ regions, in contrast to FAP- clusters, exhibited dense fibrosis, distinct metabolic profiles, and altered immune signatures, supporting the use of combined FAP-targeted radionuclide therapy with radiosensitizers.
L. Tashireva, A. Kalinchuk, E. Shmakova et al.· Asian Pacific Journal of Can...· 0 citations
This study identified three reproducible TNBC ecosystem subtypes that encode distinct spatial tumor-microenvironment architectures and clinically relevant treatment-response phenotype that provide the basis for subtyping and candidate therapeutic vulnerabilities.
Z. Mesrizadeh, Kavitha Mukund, Lu Yang et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.